Downgrading of regulation in regenerative medicine
- 16 August 2019
- journal article
- editorial
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 365 (6454) , 644-646
Abstract
What should be a firm commitment to product efficacy is threatened by economic competitionKeywords
This publication has 4 references indexed in Scilit:
- Regulatory brokerage: Competitive advantage and regulation in the field of regenerative medicineSocial Studies of Science, 2019
- Japan’s approval of stem-cell treatment for spinal-cord injury concerns scientistsNature, 2019
- ‘Reprogrammed’ stem cells approved to mend human hearts for the first timeNature, 2018
- Introduction of new therapeutic drugs in the United States and Great Britain: An international comparisonClinical Pharmacology & Therapeutics, 1973